Pharvaris N.V. (PHVS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
PHVS currently has 65.2M outstanding shares. with moderate dilution risk from 27.4M authorized shares representing 42.0% potential dilution. The company has diluted shareholders by 19.92% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 02, 2026 |
20-F filing | 65.2M shares outstanding |
65M | 27M |
| Apr 07, 2025 |
20-F filing | 54.4M shares outstanding |
54M | 27M |
| Apr 10, 2024 |
20-F filing | 52.3M shares outstanding |
52M | 27M |
| Aug 07, 2023 |
F-3 filing: This F-3 filing relates to the resale of 6,951,340 ordinary shares by selling securityholders, who acquired these shares in a private placement. The company will not receive any proceeds from the sale of these shares. |
34M | 27M |
| Apr 05, 2023 |
20-F filing | 33.8M shares outstanding |
34M | 20M |
| Mar 29, 2022 |
20-F filing | 33.2M shares outstanding |
33M | 20M |
| Mar 02, 2022 |
F-3 filing: Pharvaris N.V. may offer ordinary shares, debt securities, warrants, purchase contracts or units, with an aggregate initial offering price not exceeding $350,000,000. |
4.9M | 20M |
| Apr 29, 2021 |
20-F filing | 4.9M shares outstanding |
4.9M | 0 |
| Jan 15, 2021 |
F-1 filing: This F-1 filing relates to an offering of ordinary shares. The company intends to use the net proceeds from this offering to develop its product candidates PHVS416 and PHVS719, for additional clinical development and product discovery, and for general corporate purposes. They have applied to list their ordinary shares on the Nasdaq Global Market under the symbol PHVS. |
N/A | 0 |